Jasper Therapeutics (JSPR) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on July 31, 2026, with voting on director elections, auditor ratification, and executive compensation approval.

• Shareholders of record as of June 5, 2026, are eligible to vote; 28,009,802 shares outstanding.

• Proxy materials are distributed primarily via the Internet to reduce costs and environmental impact.

Voting matters and shareholder proposals

• Shareholders will vote on electing two Class II directors, ratifying PricewaterhouseCoopers LLP as auditor, and approving executive compensation on an advisory basis.

• Board recommends voting FOR all proposals.

• Shareholders may submit proposals for the 2027 meeting by February 18, 2027, and director nominations between April 2 and May 2, 2027.

Board of directors and corporate governance

• Board consists of seven members, divided into three staggered classes; majority are independent.

• Nominees for election: Judith Shizuru, M.D., Ph.D. and Tom Wiggans.

• Board committees include Audit, Compensation, Nominating and Corporate Governance, and Research and Development.

• Board leadership is separated between Executive Chairperson and CEO roles.

• Board and committees meet regularly, with all directors attending at least 75% of meetings.